Skip to main content

Table 3 Top 10 most common DMTs during each of the first four lines of therapy

From: Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States

Treatment line Medication Patient count Rank in treatment line % of patients in treatment line
1 (n = 1994) Glatiramer 693 1 34.8%
Dimethyl fumarate 539 2 27.0%
Interferon beta-1a 152 3 7.6%
Fingolimod 151 4 7.6%
Teriflunomide 142 5 7.1%
Ocrelizumab 120 6 6.0%
Natalizumab 85 7 4.3%
Interferon beta-1b 30 8 1.5%
Peginterferon beta-1a 30 8 1.5%
Rituximab 28 10 1.4%
2 (n = 563) Dimethyl fumarate 117 1 20.8%
Teriflunomide 88 2 15.6%
Ocrelizumab 83 3 14.7%
Fingolimod 82 4 14.6%
Natalizumab 58 5 10.3%
Glatiramer 55 6 9.8%
Interferon beta-1a 31 7 5.5%
Interferon beta-1b 10 8 1.8%
Peginterferon beta-1a 8 9 1.4%
Glatiramer & Dimethyl fumarate 7 10 1.2%
3 (n = 115) Ocrelizumab 23 1 20.0%
Dimethyl fumarate 21 2 18.3%
Natalizumab 16 3 13.9%
Teriflunomide 16 4 13.9%
Fingolimod 11 5 9.6%
Glatiramer 10 6 8.7%
Interferon beta-1a 8 7 7.0%
Alemtuzumab 4 8 3.5%
Peginterferon beta-1a 2 9 1.7%
Rituximab 2 9 1.7%
4 (n = 18) Ocrelizumab 7 1 38.9%
Alemtuzumab 3 2 16.7%
Natalizumab 3 3 16.7%
Glatiramer 2 4 11.1%
Dimethyl fumarate 1 5 5.6%
Dimethyl fumarate & Interferon beta-1b 1 5 5.6%
Teriflunomide 1 5 5.6%